National and Kapodistrian University of Athens
Μελέτη και κλινική αξιολόγηση των κυκλοφορούντων microRNAs ως νέων βιοδεικτών καρκίνου
Abstract
dc:descriptionCirculating miRNAs have intensively attracted a lot of interest as promising blood based biomarkersfor diagnosis, prognosis and therapy monitoring of cancer patients.This growing interest for the determination of circulating miRNAs concentration levels in plasmarequires robust methodologies for their quantification, such as RT-qPCR, as well as carefulconsideration of the effects of pre-analytical and analytical parameters on the isolation, stability andquantification of circulating miRNAs.In the present study, the effect of four different miRNA isolation systems and different storageconditions of plasma samples were evaluated respecting to quantitation of circulating miRNAs usingRT-qPCR. The evaluation was based on the recovery of an exogenous control that was added inknown amount in all samples and relative recoveries of endogenous miRNAs. Besides, the stabilityof extracted miRNAs during long term storage as well as the effect of data normalization procedureon the quantification of circulating miRNAs in plasma were studied.Silica-column based RNA extraction methods are more effective and reliable in respect to TRIzol LS.Circulating miRNAs are more stable when plasma samples are kept at -70˚C. After extraction,miRNAs remain stable for up to one year at -70oC. When normalization is based on a combination of an endogenous and an exogenous control miRNA, differences in miRNAs recovery and differencesin cDNA synthesis between samples are compensated.Subsequently, we proceeded to the study and clinical evaluation of circulating miRNAs in plasmasamples and corresponding primary tissues of two cancer types: non-small cell lung cancer (NSCLC)and breast cancer which are very frequent both in Greece and all over the world according tobibliography reports.Thus, we measured the expression levels of miR-21, miR-126*, miR-451, miR-30d, miR-10a and miR 30e-5p in primary tumors and corresponding plasma samples of NSCLC patients. In a next step, the results from primary tumors and plasma samples were compared to be ascertained whether the expression levels of miRNAs in primary tissues are reflected by the concentration levels of circulating miRNAs in plasma. In addition to, we studied the correlation between the expression levels of miRNAs in tissues or concentrationlevels of circulating miRNAs in plasma and the clinicopathological characteristics of patients for both types of cancer. At last, we evaluated their prognostic significance performing Kaplan-Meier survival analysis for DFI and OS.The expression levels of miR-451, miR-126* and miR-30d are reduced in primary cancerous tissues in comparison to adjacent non-cancerous tissues, while those of miR-21 are increased. Besides, in the present study, the expression levels of miR-10a and miR-30e-5p were studied for the first time in bibliography and the results indicated that miR-30e-5p expression levels are reduced in primary cancerous tissues in comparison to adjacent non-cancerous tissues, while miR-10a expression levels are not differentiated. The increased levelsof miR-21 in primary tumors of NSCLC patients are associated with shorter DFI and OS.Concerning the concentration levels of circulating miRNAs in corresponding plasma samples of the same NSCLC patients, circulating miR-21 concentration levels are elevated in plasma samples of these patients in comparison to healthy plasma samples and are associated with shorter DFI and OS, while miR-10a concentration levels are reduced and are associated with short DFI. Lastly, the concentration levels of miR30e-5p are increased in plasma samples of NSCLC patients and are correlated with short OS.In respect to breast cancer patients, we measured the expression levels of miR-21, miR-146a, miR-210, miR31 and miR-200c in primary tumors and corresponding plasma samples of the same patients. Subsequently, these results were correlated: a) between the two different biologic samples; b) with the clinicopathological characteristics of patients; c) with progression free survival (PFS) and overall survival (OS) of patients and d) with the presence of circulating tumor cells in peripheral blood of breast cancer patient.The expression levels of miR-21, miR-146a, miR-210 and miR-200c are increased, while those of miR-31 are reduced, in primary tumor tissues of breast cancer patients in comparison to healthy tissues and it is interesting the fact that the expression levels of miR-21, miR-146a and miR-210 are higher in operable patients than metastatic patients while those of miR-31 are lower in metastatic patients than operable patients. The increasedexpression levels of miR-21 and miR-146a are correlated with ER and PR absence in primary tumor tissues, while the reduced expression levels of miR-31 are associated with advanced stage.The concentration levels of miR-21, miR-146a and miR-210 are higher in plasma samples of breast cancer patients than healthy donors, while those of miR-31 and miR-200c are not detectable. The increased concentration levels of miR-210 in plasma samples are associated with increased tumor size, advanced stage and PR absence. It’s noteworthy that the increased concentration levels of circulating miR-21 in plasma samples of metastatic breast cancer patients are correlated for the first time in bibliography both with short PFS and OS. In additional to, the increased concentration levels of circulating miR-146a and miR-210 in plasma samples are also associated for the first time with short PFS and OS, respectively, of metastatic breast cancer patients Concerning the CTC presence in the peripheral blood of breast cancer patients, the expression levels of miR21and miR-146a are higher in primary tumor tissues of CK-19 negative patients than CK-19 positive patients, while the expression levels of miR-31 are lower in CK-19 positive patients than CK-19 negative patients.Besides, the increased expression levels of miR-21 in primary tissues of CK-19 positive patients are associated with increased tumor size and ER/PR absence.The concentration levels of circulating miR-21 are higher in plasma samples of CK-19 positive patients than CK-19 negative patients, while the increased concentration levels of circulating miR-210 in plasma samples of CK-19 positive patients are associated with increased size of the primary tumor (>3cm).In conclusion, the results of the present study reinforce the view that circulating miRNAs are verypromising blood based biomarkers since their concentration is associated with clinical outcome ofcancer patients. The tissue specificity of certain miRNAs can be exploited in the cancer origin revelation using circulating miRNAs panels as diagnostic and prognostic tools. Additionally, the expression profile of miRNAs between primary tumor and plasma is not identical and this fact could be useful for the understanding of changes happening during cancer progression and metastasis. At last, it is notable that the concentration levels of circulating miRNAs can discriminate between early and metastatic cancer patients and are associated with the presence of metastasis in patients.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Sourvinou, Ioanna-Olga
- Σουρβίνου, Ιωάννα-Όλγα
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44086